Bionano Genomics Ownership
| BNGO Stock | USD 3.25 0.05 1.52% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 67.6 M | Current Value 85.9 M | Avarage Shares Outstanding 20.4 M | Quarterly Volatility 21.6 M |
Bionano |
Bionano Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.18. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bionano Genomics recorded a loss per share of 138.0. The entity had not issued any dividends in recent years. The firm had 1:60 split on the 27th of January 2025. Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 299 people. For more info on Bionano Genomics please contact Robert MBA at 858 888 7600 or go to https://www.bionano.com.Besides selling stocks to institutional investors, Bionano Genomics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bionano Genomics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bionano Genomics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bionano Genomics Quarterly Liabilities And Stockholders Equity |
|
Bionano Genomics Insider Trades History
Less than 1% of Bionano Genomics are currently held by insiders. Unlike Bionano Genomics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bionano Genomics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bionano Genomics' insider trades
Bionano Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bionano Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bionano Genomics backward and forwards among themselves. Bionano Genomics' institutional investor refers to the entity that pools money to purchase Bionano Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 17 K | Advisor Group Holdings, Inc. | 2024-09-30 | 13.3 K | Millennium Management Llc | 2024-09-30 | 10.1 K | Sbi Securities Co Ltd | 2024-12-31 | 9.1 K | Citigroup Inc | 2024-09-30 | 7 K | Crédit Agricole S.a. | 2024-09-30 | 2.6 K | Wells Fargo & Co | 2024-09-30 | 2.2 K | Jpmorgan Chase & Co | 2024-09-30 | 1.5 K | Group One Trading, Lp | 2024-09-30 | 1.5 K | Geode Capital Management, Llc | 2024-09-30 | 882.9 K | Blackrock Inc | 2024-09-30 | 614.2 K |
Bionano Genomics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bionano Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bionano Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bionano Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bionano Genomics Outstanding Bonds
Bionano Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bionano Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bionano bonds can be classified according to their maturity, which is the date when Bionano Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Bionano Genomics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of February 2025 Other Reports | ViewVerify | |
8K | 10th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of January 2025 Other Reports | ViewVerify |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.91 | FNA | Paragon 28 | PairCorr |
| 0.78 | LUCD | Lucid Diagnostics Buyout Trend | PairCorr |
| 0.77 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.68 | NYXH | Nyxoah | PairCorr |
| 0.67 | CMRX | Chimerix Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (138.00) | Revenue Per Share | Quarterly Revenue Growth (0.35) | Return On Assets | Return On Equity |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.